Furkan Bahar

Furkan Bahar

Auto-generated profile, based on publicly available information

Furkan Bahar

Department of Medicine, Mount Auburn Hospital Harvard Medical School Cambridge Massachusetts USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Annals of Internal Medicine
Verified
Journal Article
Closed access
AKAlbert Ko
Albert Ko
YCYu-Cheng Chang
Yu-Cheng Chang
FBFurkan Bahar
Furkan Bahar
TWTsu Hsien Wang
Tsu Hsien Wang
NXNutchapon Xanthavanij
Nutchapon Xanthavanij
SLShuwen Lin
Shuwen Lin
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for type 2 diabetes mellitus (T2DM) and overweight or obesity, but their association with cancer is unclear. To investigate the risk for obesity-related cancer associated with GLP-1RAs. PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials from inception to August 2025. Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma. Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool, and certainty of evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Odds ratios (ORs) were pooled using random-effects meta-analysis. The review included 48 trials involving 94 245 participants. GLP-1RAs probably have little or no effect on risk for thyroid cancer (OR, 1.37 [95% CI, 0.82 to 2.31]; 1 fewer to 9 more cases per 10 000 patients treated), pancreatic cancer (OR, 0.84 [CI, 0.53 to 1.35]; 9 fewer to 6 more per 10 000), breast cancer (OR, 0.95 [CI, 0.60 to 1.49]; 10 fewer to 12 more per 10 000), or kidney cancer (OR, 1.12 [CI, 0.78 to 1.60]; 5 fewer to 13 more per 10 000) (moderate certainty). GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty). The effect on gastric cancer is very uncertain. Results were consistent in sensitivity analyses of trials with low risk of bias and studies of semaglutide or tirzepatide and across subgroups stratified by follow-up duration, population, GLP-1RA class, weight loss profile, dose, and duration of action. The included trials were not designed to evaluate cancer outcomes and had short follow-up. GLP-1RAs may have little or no effect on risk for obesity-related cancers. Longer-term studies are needed to clarify potential risks or benefits. None. (PROSPERO: CRD42024608365).


20 December 2023 in Modern Rheumatology Case Reports
Verified
Journal Article
Closed access
PDF file
FBFurkan Bahar
Furkan Bahar
SUSerdal Ugurlu
Serdal Ugurlu
Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder predominantly characterised by periodic fever, abdominal pain, and joint manifestations. It can exhibit various atypical presentations. However, cases of FMF concurrently presenting with chronic thrombosis and myositis have not been previously reported. A 41-year-old male presented with alternating severe bilateral leg pain, stiffness, and localised swellings without fever or abdominal symptoms. His history included inflammatory joint pain treated with prednisolone. Physical examination revealed leg pain, limited ankle joint movement, and tender swellings in thighs, forearms, and feet. Collateral abdominal veins were also observed. Unresponsive to prednisolone and colchicine, the patient underwent MRI, revealing muscle inflammation in both legs and thighs and chronic thrombosis in the infrarenal inferior vena cava. Genetic testing confirmed the heterozygotic M694V mutation, diagnosing an atypical FMF. This case uniquely showcases coexisting myositis and chronic thrombosis in FMF. Myalgia is common in FMF, with M694V mutation associated with severe muscular symptoms. The lack of fever and myositis findings differentiate our case from protracted febrile myalgia syndrome. FMF’s chronic inflammatory state is known to influence thrombosis risk, and our findings align with this association. Chronic thromboembolism and myositis together signify an unusual clinical presentation of FMF. This case highlights the potential for FMF to present with complex manifestations beyond the conventional symptoms. Myositis and vascular involvement should prompt consideration of FMF diagnosis when combined with patient history, clinical features, and laboratory results. These rare associations underscore the need for further research to enhance understanding of FMF’s diverse clinical spectrum.

6 January 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
AEAbdülkadir Erçalışkan
Abdülkadir Erçalışkan
DEDuygu Seyhan Erdoğan
Duygu Seyhan Erdoğan
FBFurkan Bahar
Furkan Bahar
ÇBÇağrı Belli
Çağrı Belli
DODamla Ortaboz
Damla Ortaboz
AEAhmet Emre Eskazan
Ahmet Emre Eskazan
Aim: This study evaluates the efficacy and safety of rituximab biosimilars (BRs) compared to the original rituximab (MAB) administered intravenously, particularly from the aspect of switching and switch directions. Materials and Methods: This retrospective study included patients treated with BR and/or MAB for hematological diagnoses. For efficacy analyses, patients with DLBCL or FL receiving BR during R-CHOP were compared with two matched-control groups treated only with MAB. Patients completing fewer than two consecutive cycles of BR or MAB were excluded. Study groups were classified as BR-only or switching (S). Switching was defined as replacing rituximab between MAB and BR for at least two consecutive cycles. Switch directions are denoted as OB (MAB to BR), BO (BR to MAB), and M (multiple switches). Results: Toxicity was evaluated in 185 patients. Responses of 69 DLBCL and 33 FL patients were compared with 52 DLBCL and 11 FL patients treated only with MAB. Median follow-up was 20 months. In DLBCL, MAB had significantly higher interim ORR and CR than BR and S (p = 0.04), but not at end-of-treatment (p = 0.081, 0.125). FL responses were similar across groups. Among 1266 rituximab infusions, 32 (2.5%) IRRs occurred, 78% during first-cycle. No difference in IRR or first-cycle reactions was seen between BR and S (p = 0.175, 0.429). IRR rates in S subgroups were 1/37 (OB), 8/35 (BO), and 4/28 (M), with BO direction higher than OB (p = 0.029). Conclusion: Our findings confirm that intravenous BRs and MAB are equivalent in efficacy and toxicity, while a direction-specific increase in IRRs occurs when switching from BR to MAB, warranting further prospective studies to clarify clinical significance and guide safer treatment transitions.

30 October 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
PSPratik Shah
Pratik Shah
ASAdit Singhal
Adit Singhal
FBFurkan Bahar
Furkan Bahar
TWTsu Hsien Wang
Tsu Hsien Wang
ANAnita Ng
Anita Ng
CCCho‐Han Chiang
Cho‐Han Chiang

15 June 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
CCCho‐Han Chiang
Cho‐Han Chiang
FBFurkan Bahar
Furkan Bahar
YCYu‐Cheng Chang
Yu‐Cheng Chang
TWTsu Hsien Wang
Tsu Hsien Wang
YHYuan Ping Hsia
Yuan Ping Hsia
CCCho‐Hung Chiang
Cho‐Hung Chiang